Background: Immunotherapy has gained momentum with the discovery of novel antibodies targeting immunosuppressive proteins. HLA-E, a non-classical major histocompatibility complex class I (MHC-I) protein, exhibits immunosuppressive properties, potentially influencing tumor immune evasion mechanisms. The association between Human Leukocyte Antigen E (HLA-E) expression and outcomes in solid tumors remains unclear.
Methods: A systematic review of MEDLINE, Scopus, and the Cochrane Library up to March 15, 2024, was conducted following the PRISMA guidelines. Studies investigating HLA-E expression in solid tumors and its association with OS and DFS were included. Statistical analysis was performed using Comprehensive Meta-Analysis (version 3.0) with random-effects models.
Results: After screening 657 articles, 11 studies were included, comprising a total of 1781 patients. The studies encompassed a variety of cancer types, follow-up periods, and staging details, with the majority focusing on non-metastatic cases. Notably, three studies evaluated colorectal cancer, while others focused on pancreatic, esophageal, brain, renal cell, gastric, endometrial, cervical, and hepatocellular carcinomas. The mean age of the patients was 59.81 ± 2.01 years, and the median follow-up period was 57.45 ± 8.91 months. HLA-E expression demonstrated no statistically significant association with OS (HR 0.913, 95% CI = 0.567-1.469; P=0.707), with significant heterogeneity observed (I2 = 84%). However, HLA-E non-expression was significantly associated with improved DFS (HR 1.406, 95% CI = 1.027-1.930; P=0.03), with moderate heterogeneity (I2 = 45%).
Conclusion: This systematic review highlights that HLA-E expression in solid tumors could be a biomarker of better prognosis, measured by DFS. These findings align with the clinical benefit observed for agents targeting this pathway. However, further studies should be performed to confirm these preliminary observations.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024527598, identifier CRD42024527598.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891020 | PMC |
| http://dx.doi.org/10.3389/fonc.2025.1525924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In-depth analysis of the safety of CAR-T cell therapy for solid tumors.
Front Immunol
March 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFNasopharyngeal Angiofibroma: Karyotyping Profile and Florescent In-Situ Hybridization Analysis with C-Myelocytomatosis, Tumor Suppressor p53 and CEP-X/Y Probes.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Otorhinolaryngology and Head and Neck Surgery, King George Medical University, Lucknow, India.
Unlabelled: The chromosomal characterization of nasopharyngeal angiofibroma (NPF) of Indian origin seems important as it is consistently absent in literature. Routine karyotyping (G-banding) and fluorescence in situ hybridization (FISH) analysis was undertaken using CMYC, TP53 CEPX/Y probes in 9 cases of NPF wherein chromosomal characteristics were correlated with clinical parameters. Karyotype profile of venous sample from every case was normal.
View Article and Find Full Text PDFComprehensive investigation of proteoglycan gene expression in breast cancer: Discovery of a unique proteoglycan gene signature linked to the malignant phenotype.
Proteoglycan Res
January 2025
Department of Pathology and Genomic Medicine, and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Solid tumors present a formidable challenge in oncology, necessitating innovative approaches to improve therapeutic outcomes. Proteoglycans, multifaceted molecules within the tumor microenvironment, have garnered attention due to their diverse roles in cancer progression. Their unique ability to interact with specific membrane receptors, growth factors, and cytokines provides a promising avenue for the development of recombinant proteoglycan-based therapies that could enhance the precision and efficacy of cancer treatment.
View Article and Find Full Text PDFAssociation between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis.
Front Oncol
February 2025
Department of Medical Oncology, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), and CIBERONC, Madrid, Spain.
Background: Immunotherapy has gained momentum with the discovery of novel antibodies targeting immunosuppressive proteins. HLA-E, a non-classical major histocompatibility complex class I (MHC-I) protein, exhibits immunosuppressive properties, potentially influencing tumor immune evasion mechanisms. The association between Human Leukocyte Antigen E (HLA-E) expression and outcomes in solid tumors remains unclear.
View Article and Find Full Text PDFIsolated Cystic Neck Mass as Only Presentation of Tonsillar Carcinoma.
Indian J Otolaryngol Head Neck Surg
February 2025
Dept. of Pathology, IMS and SUM Hospital, Bhubaneswar, India.
Isolated cystic cervical swelling may be a presentation of a branchial cyst, tubercular lymphadenitis, or maybe a metastatic lymphadenopathy from different head and neck subsites like pharynx and thyroid, etc. The location or level of swelling may give hints towards the primary pathology from where it spreads. Aspiration cytology and radiology sometimes fail to confirm its malignant nature and the primary site of origin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!